Pinnacle Bank Announces Earnings for Second Quarter of 2025
GILROY, Calif.–(BUSINESS WIRE)–OTCQB: PBNK – Pinnacle Bank, headquartered in Gilroy, California, announced today unaudited net income for the three... Read more.
Liberty Energy Inc. Announces Second Quarter 2025 Financial and Operational Results
DENVER–(BUSINESS WIRE)–Liberty Energy Inc. (NYSE: LBRT; “Liberty” or the “Company”) today reported second quarter 2025 financial and operational... Read more.
TriSalus Life Sciences Announces Expiration and Results of Exchange Offer and Consent Solicitation Relating to Series A Convertible Preferred Stock
WESTMINSTER, Colo.–(BUSINESS WIRE)–TriSalus Life Sciences® Inc. (Nasdaq: TLSI), a company focused on improving outcomes for patients with solid tumors,... Read more.
Targepeutics Announces Strategic Investment from Yuvaan Tiwari Foundation to Support Advancement of GB13 into Clinical Trials for DIPG
HUMMELSTOWN, Pa.–(BUSINESS WIRE)–Targepeutics, a biotech company dedicated to developing targeted therapies for aggressive pediatric brain cancers, is... Read more.
KBRA Releases Research – Retail Sales Return to Growth in June as Inflationary Expectations Ease
NEW YORK–(BUSINESS WIRE)–#creditratingagency–KBRA releases research examining last month’s bounce in retail sales amid signs that the Trump... Read more.
CORRECTING and REPLACING EVERTEC Declares Quarterly Dividend on Common Stock
SAN JUAN, Puerto Rico–(BUSINESS WIRE)–First paragraph, first sentence of release should read: …per share on July 24, 2025 to be paid on September... Read more.
Bitwise Announces Monthly Distributions for IMST, ICOI, IMRA, and IGME
SAN FRANCISCO–(BUSINESS WIRE)–Bitwise Asset Management, a leading crypto asset manager, today announced the monthly distributions for its suite of Option... Read more.
Pembina Pipeline Reaches Settlement With Shippers On Alliance Pipeline
All financial figures are in Canadian dollars unless otherwise noted. CALGARY, Alberta–(BUSINESS WIRE)–Pembina Pipeline Corporation (“Pembina”)... Read more.
Exelixis’ Partner Ipsen Receives European Commission Approval for CABOMETYX® (cabozantinib) for Patients with Previously Treated Advanced Neuroendocrine Tumors
– Approval is based on the phase 3 CABINET pivotal trial, in which CABOMETYX demonstrated a statistically significant and clinically meaningful improvement in... Read more.
Incyte To Present Initial Data for its TGFβR2×PD-1-directed Bispecific Antibody (INCA33890) and its Selective Inhibitor of G12D-mutated KRAS (INCB161734) at the European Society of Medical Oncology (ESMO) Congress 2025
– Mini oral presentation to highlight initial Phase 1 data of INCA33890, a promising TGFβR2×PD-1-directed bispecific antibody, in patients with advanced... Read more.